These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16854062)

  • 1. Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase.
    Rafi SB; Cui G; Song K; Cheng X; Tonge PJ; Simmerling C
    J Med Chem; 2006 Jul; 49(15):4574-80. PubMed ID: 16854062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
    Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ
    J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
    Shah P; Siddiqi MI
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
    Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
    ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
    Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
    Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
    Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
    Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design and Pharmacophore-Based Virtual Screening of Combinatorial Library of Triclosan Analogues Active against Enoyl-Acyl Carrier Protein Reductase of
    Bieri C; Esmel A; Keita M; Owono LCO; Dali B; Megnassan E; Miertus S; Frecer V
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
    Lu X; Lv M; Huang K; Ding K; You Q
    Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of protein-ligand binding interactions of enoyl-ACP reductase (FabI) by native MS reveals allosteric effects of coenzymes and the inhibitor triclosan.
    Joyner PM; Tran DP; Zenaidee MA; Loo JA
    Protein Sci; 2022 Mar; 31(3):568-579. PubMed ID: 34882866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of triclosan inhibition of bacterial fatty acid synthesis.
    Heath RJ; Rubin JR; Holland DR; Zhang E; Snow ME; Rock CO
    J Biol Chem; 1999 Apr; 274(16):11110-4. PubMed ID: 10196195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
    Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
    Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
    Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.
    Mehboob S; Truong K; Santarsiero BD; Johnson ME
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Nov; 66(Pt 11):1436-40. PubMed ID: 21045289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan.
    Otero JM; Noël AJ; Guardado-Calvo P; Llamas-Saiz AL; Wende W; Schierling B; Pingoud A; van Raaij MJ
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Oct; 68(Pt 10):1139-48. PubMed ID: 23027736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for triclosan activity involves a flipping loop in the active site.
    Qiu X; Janson CA; Court RI; Smyth MG; Payne DJ; Abdel-Meguid SS
    Protein Sci; 1999 Nov; 8(11):2529-32. PubMed ID: 10595560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.
    Rafi S; Novichenok P; Kolappan S; Stratton CF; Rawat R; Kisker C; Simmerling C; Tonge PJ
    J Biol Chem; 2006 Dec; 281(51):39285-39293. PubMed ID: 17012233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.
    Priyadarshi A; Kim EE; Hwang KY
    Proteins; 2010 Feb; 78(2):480-6. PubMed ID: 19768684
    [No Abstract]   [Full Text] [Related]  

  • 18. Trapping of the Enoyl-Acyl Carrier Protein Reductase-Acyl Carrier Protein Interaction.
    Tallorin L; Finzel K; Nguyen QG; Beld J; La Clair JJ; Burkart MD
    J Am Chem Soc; 2016 Mar; 138(12):3962-5. PubMed ID: 26938266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
    Sharma SK; Kumar G; Kapoor M; Surolia A
    Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the variation in triclosan affinity to enoyl reductases.
    Pidugu LS; Kapoor M; Surolia N; Surolia A; Suguna K
    J Mol Biol; 2004 Oct; 343(1):147-55. PubMed ID: 15381426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.